![Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study | Cancer Chemotherapy and Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study | Cancer Chemotherapy and](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00280-021-04296-0/MediaObjects/280_2021_4296_Fig4_HTML.png)
Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study | Cancer Chemotherapy and
![FeDeriCa & PHranceSCa Clinical Trial Design | PHESGO® (pertuzumab / trastuzumab / hyaluronidase-zzfx) FeDeriCa & PHranceSCa Clinical Trial Design | PHESGO® (pertuzumab / trastuzumab / hyaluronidase-zzfx)](https://www.phesgo-hcp.com/content/dam/gene/phesgo-hcp/mobile/FeDeriCa-trial-design-mobile.genecoreimg.480.png)
FeDeriCa & PHranceSCa Clinical Trial Design | PHESGO® (pertuzumab / trastuzumab / hyaluronidase-zzfx)
![Results from the FeDeriCa trial: are we reducing the burden of breast cancer treatment? - The Lancet Oncology Results from the FeDeriCa trial: are we reducing the burden of breast cancer treatment? - The Lancet Oncology](https://www.thelancet.com/cms/asset/bb65cf25-fda2-4644-be63-1ea880f39b99/fx1.jpg)
Results from the FeDeriCa trial: are we reducing the burden of breast cancer treatment? - The Lancet Oncology
![MONDIALI. FEDERICA VENTURELLI E' BRONZO NELLA CRONO JUNIOR. IL TITOLO E' DELL'AUSTRALIANA WILSON HAFFENDEN MONDIALI. FEDERICA VENTURELLI E' BRONZO NELLA CRONO JUNIOR. IL TITOLO E' DELL'AUSTRALIANA WILSON HAFFENDEN](https://www.tuttobiciweb.it/article/1691667975/photo-medium.jpg)
MONDIALI. FEDERICA VENTURELLI E' BRONZO NELLA CRONO JUNIOR. IL TITOLO E' DELL'AUSTRALIANA WILSON HAFFENDEN
![Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study - The Lancet Oncology Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/600877ae-9d38-45e8-9394-7ecbde8ac7ca/gr1_lrg.jpg)
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study - The Lancet Oncology
![Saucony Dolomiti Extreme Trail, il tedesco Tobias Fritz e la vicentina Federica Boifava firmano la 103 K | Bellunopress - Dolomiti Saucony Dolomiti Extreme Trail, il tedesco Tobias Fritz e la vicentina Federica Boifava firmano la 103 K | Bellunopress - Dolomiti](https://www.bellunopress.it/wp-content/uploads/2023/06/federica-boifava-vincitrice-103-K-dolomiti-extreme-trial.jpg)
Saucony Dolomiti Extreme Trail, il tedesco Tobias Fritz e la vicentina Federica Boifava firmano la 103 K | Bellunopress - Dolomiti
Federica Bitonti - Senior Director Clinical Site Operations (Italy, Bulgaria Israel) - Pfizer | LinkedIn
![Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study - ScienceDirect Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0959804921002148-gr1.jpg)
Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study - ScienceDirect
![Tokyo 2020, Nuoto, Matteo Giunta: “L'obiettivo di Federica Pellegrini alle Olimpiadi è la finale dei 200 stile libero" - Eurosport Tokyo 2020, Nuoto, Matteo Giunta: “L'obiettivo di Federica Pellegrini alle Olimpiadi è la finale dei 200 stile libero" - Eurosport](https://imgresizer.eurosport.com/unsafe/1200x0/filters:format(jpeg)/origin-imgresizer.eurosport.com/2020/01/03/2745769-56737390-2560-1440.jpg)